Valence Life Sciences Announces Promotion of Scott Morenstein and Hiring of Robert Ferraioli
- Late-Stage Life Sciences Firm Leverages Success to Expand Team
NEW YORK and SAN DIEGO, April 26, 2012 (GLOBE NEWSWIRE) -- Valence Life Sciences, the independent entity formed in 2012 as successor to Caxton Advantage Venture Partners, announces the promotion of Scott Morenstein to Managing Director. Mr. Morenstein joined Caxton Advantage in 2007 as an Associate after receiving an MBA from Harvard Business School. Mr. Morenstein started his career at Lehman Brothers as a healthcare investment banker and equity research analyst. Mr. Morenstein played a key role in the sale of Caxton Advantage portfolio company Gemin X Pharmaceuticals to Cephalon (now Teva Pharmaceutical) and his deals include investments in Sunesis and ArQule. Valence Life Sciences further announces the hiring of Robert Ferraioli, CPA as Vice President, Controller. Mr. Ferraioli will be responsible for overseeing Valence Life Sciences' accounting and administrative functions. Mr. Ferraioli has a diverse and extensive accounting background with experience in asset management, public accounting, and financial services. Mr. Ferraioli joins Valence Life Sciences from Automotive Resources International where he was responsible for the development of financial forecasts and strategic planning models. He was formerly Assistant Controller at Caxton Associates where he worked from 2000 to 2009.
Valence Life Sciences' investment team who include Eric Roberts and Rachel Leheny, Jay Cecil, and Scott Morenstein will continue to manage Caxton Advantage's nine portfolio companies for which the team have thus far generated realizations in Gemin X Pharmaceuticals (sold to Cephalon, now Teva Pharmaceutical, for up to $525 million) and Corthera (sold to Novartis for up to $620 million) and through the initial public offering of Anthera Pharmaceuticals. In addition, Caxton Advantage has made substantial investments in Vivus, Sunesis, ArQule, Regado, Gentium and Transcept. Today, only one private company remains in Caxton Advantage's portfolio.
About Valence Life Sciences
Valence Life Sciences is a New York-and San Diego-based life sciences venture capital firm founded by Dr. Rachel Leheny and Eric Roberts to focus on clinical development stage private and micro-cap public companies. The other members of Valence Life Sciences' investment team include managing directors, Jay Cecil and Scott Morenstein.
CONTACT: Investor Relations: The Trout Group
Brian Korb
646-378-2923
Valence Life Sciences, LLC
Eric Roberts
212-891-1160
© 2012 GlobeNewswire, Inc, All Rights Reserved.
RECENT VALENCE NEWS
May 22, 2020
CalciMedica Raises $15 Million in Series C Financing Round Led by Valence Life Sciences
May 20, 2020
Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing
January 23, 2020
December 9, 2019
Print